CClinicalTrials.gg
CompletedNCT01590147SIPSUpdated Aug 15, 2018

Supportive Intervention Programs Study

An interventional study of Yoga therapy and questionnaire administration in Fatigue, Nausea and Vomiting and Pain, sponsored by Wake Forest University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by Wake Forest University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized clinical trial studies the preliminary efficacy of a yoga skills training (YST) compared to counseling and education (CE) for reducing treatment-related symptoms in patients with colorectal cancer who are receiving chemotherapy. The YST may reduce fatigue, other treatment-related symptoms, and improve the quality of life (QOL) of patients with colorectal cancer. It is not yet known whether YST is more effective then CE in reducing these outcomes.

Read the detailed description

OBJECTIVES:

I. To establish the feasibility of implementing a YST among patients undergoing chemotherapy. This includes the feasibility of implementing yoga in a treatment setting, and patient recruitment, adherence, and retention.

II. To obtain preliminary data on the efficacy of a YST for reducing fatigue among patients undergoing chemotherapy.

III. To obtain exploratory data on the impact of a YST on other treatment-related symptoms (e.g., pain, distress, nausea) and QOL.

IV. To obtain exploratory data on the impact of a YST on potential psychological (self-efficacy for coping with cancer, response expectancies for symptoms) and physiological (interleukin [IL]-6 [IL-6], IL-1 Receptor Antagonist [IL-1Ra], tumor necrosis factor- alpha [TNF-a], soluble TNF receptor I [sTNFRI], C-reactive protein [CRP]) mediators that may explain the impact of the YST on fatigue.

OUTLINE: Patients (n=20) are randomized to 1 of 2 treatment arms.

ARM I: Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a compact disc (CD) recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.

ARM II: Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.

The interventions (Week 2, Week 4, Week 6) and assessments (Week 0, Week 4, Week 8) are implemented during visits for chemotherapy (every two weeks).

02

Conditions studied

  • Fatigue
  • Nausea and Vomiting
  • Pain
  • Recurrent Colon Cancer
  • Recurrent Rectal Cancer
  • Stage I-IVB Colon Cancer
  • Stage I-IVB Rectal Cancer
03

In context

Rectal Neoplasms

1,762 studies on the registry are indexed under Rectal Neoplasms; 518 are open to participants now.

This study's enrollment of 15 is below the median of 65 across 1,298 interventional studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

Wake Forest University is the lead sponsor of 116 studies on the registry; 7 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 27 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Signed protocol specific informed consent
  • Are diagnosed with colorectal cancer
  • Recruited within 2 weeks of initiating chemotherapy (including reinitiating chemotherapy after a treatment holiday of greater than or equal to 4 weeks)
  • Able to understand written and spoken English

Exclusion criteria

Exclusion Criteria:

  • Under age 18 (children with colorectal cancer)
  • Unable to read or understand English
  • Vulnerable subjects (except those who are economically or educationally disadvantaged)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Arm 1 (YST)

    Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.

    Procedure: Yoga therapy · Other: questionnaire administration · Procedure: quality-of-life assessment · Other: laboratory biomarker analysis · Other: assessment of therapy complications · Procedure: management of therapy complications

  • Active comparator
    Arm 2 (CE)

    Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.

    Other: questionnaire administration · Procedure: quality-of-life assessment · Other: laboratory biomarker analysis · Other: assessment of therapy complications · Procedure: management of therapy complications · Other: educational intervention

Interventions

  • ProcedureYoga therapy

    receive YST

  • Otherquestionnaire administration

    Ancillary studies

  • Procedurequality-of-life assessment

    Ancillary studies

  • Otherlaboratory biomarker analysis

    Correlative studies

  • Otherassessment of therapy complications

    Ancillary studies

  • Proceduremanagement of therapy complications

    Receive YST or CE

    Also known as: complications of therapy, management of

  • Othereducational intervention

    Receive CE

06

What researchers measure

Primary outcomes

  1. Feasibility of implementing a YST among patients undergoing chemotherapy (participating rate, adherence, and retention)

    The proportion of participants who participated in all study sessions and those who completed all assessments will be computed and compared by demographic characteristics and intervention group. The investigators will model the relationship between adherence and baseline scores of the measures, as well as change in scores.

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Preliminary efficacy of YST, in terms of reducing fatigue

    Measured by the Functional Assessment of Cancer Therapy - Fatigue (FACT-F) subscale. Assessed using analysis of covariance (ANCOVA) models, accounting for possible confounding variables (e.g., medication use) from baseline to post intervention.

    Time frame: At week 8

  2. Treatment related symptoms and QOL

    The Functional Assessment of Cancer Therapy- Colorectal (FACT-C; 37) will be used to evaluate overall QOL (physical, social, emotional, and functional well-being) and colorectal cancer specific symptoms (e.g., cramps in stomach, control of bowels). Assessed using ANCOVA.

    Time frame: At week 8

  3. Mediating variables (self efficacy, response expectancies, inflammatory biomarkers) intervention effect on fatigue, treatment-related symptoms, and QOL

    Assessed using a simultaneous model of the mediators and the intervention effect in the ANCOVA model.

    Time frame: Up to 8 weeks

07

Study locations

1 site
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01590147
Lead sponsor
Wake Forest University
Responsible party
Sponsor
First posted
May 2, 2012
Start date
Jun 2011
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Aug 15, 2018

Study contacts

Stephanie J Sohl, PhD
principal investigator · Wake Forest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion